FDA Under Trump: What To Expect, and Why the Unique Nature of FDA Should be Considered by the Transition Team – Catalyst Guest Column

Life Science Leader – Trump’s advance team will soon be headed to FDA’s White Oak campus to observe and learn, as planning unfolds for the transition to the new Administration. In this guest column, Catalyst President Nancy Myers explores what may be on the agenda at this stage; she also explains why FDA is different from other federal agencies, and why taking an anti-regulation stance may not result in a better environment for innovation.